Joseph Foss, MD
- Call 216.445.8137
Insurance
Is Cleveland Clinic Part of Your Insurance?
Review a list of accepted insurance plans for our Northeast Ohio locations or learn more about purchasing a contracted managed care plan.
View All PlansAbout Joseph Foss, MD
Joseph Foss, MD, is the Director of Clinical Research for General Anesthesiology in the Department of Anesthesiology at Cleveland clinic’s main campus. His specialty interests include clinical research, pain research, and clinical pharmacology, general and ambulatory anesthesia.
Dr. Foss earned his medical degree from Brown University School of Medicine in Providence, R.I. He completed a surgical internship at the University of Oregon Health Sciences Center in Portland, Ore. He also completed an anesthesia residency and a clinical pharmacology fellowship at the University of Chicago Hospitals in Chicago, Ill.
He is a Diplomate with the American Board of Anesthesiology, and a member of several medical societies, including the American Medical Association, the Ohio Society of Anesthesiologists, the American Society of Anesthesiologists and the International Anesthesia Research Society, among others.
Dr. Foss has published a number of articles in peer-reviewed journals on various topics related to anesthesiology and pharmacology. He has also lectured on the topics.
Education & Professional Highlights
Appointed
2006
Education & Fellowships
Fellowship - University of Chicago Hospitals
Clinical Pharmacology
Chicago,
IL
1990
Residency - University of Chicago Hospitals
Anesthesiology
Chicago,
IL
1989
Internship - University of Oregon Health Sciences Center
Transitional
Portland,
OH
1986
Medical Education - Brown University School of Medicine
Providence,
RI
1985
Undergraduate - Warren Alpert Medical School of Brown University Rhode Island Hospital
Providence,
RI
1981
Certifications
- Anesthesiology
Specialty Interests
Clinical pharmacology, Clinical research, General and ambulatory anesthesia, General anesthesia, Pain research
Innovations & Patents
Developed a novel drug, methylnaltrexone, which is approved for the treatment of side effects of opioid pain medications.
Research & Publications
See publications for Joseph Foss, MD.
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 1/24/2024, Dr. Foss has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Royalty Payments. Dr. Foss receives or has the right to receive royalty payments for inventions or discoveries commercialized through the companies shown below:
- NeuroTherapia, Inc.
Right to Future Distribution of Cleveland Clinic Financial Interest. Dr. Foss may receive future financial benefits from the Cleveland Clinic for inventions or discoveries commercialized through the companies shown below:
- NeuroTherapia, Inc.
Equity Dr. Foss owns stock or stock options in the following companies for activities as a founder, inventor, discover, developer:
- NeuroTherapia, Inc.
Fiduciary Role. Dr. Foss serves in a fiduciary capacity, such as an elected officer, director or chief medical officer, for the following companies or other entities:
- NeuroTherapia, Inc.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.
* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.
